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Background. Characterization of intrinsic and extrinsic factors regulating the self-renewal/division and differentiation of stem
cells is crucial in determining embryonic stem (ES) cell fate. ES cells differentiate into multiple hematopoietic lineages during
embryoid body (EB) formation in vitro, which provides an experimental platform to define the molecular mechanisms
controlling germ layer fate determination and tissue formation. Methods and Findings. The cannabinoid receptor type 1
(CB1) and cannabinoid receptor type 2 (CB2) are members of the G-protein coupled receptor (GPCR) family, that are activated
by endogenous ligands, the endocannabinoids. CB1 receptor expression is abundant in brain while CB2 receptors are mostly
expressed in hematopoietic cells. However, the expression and the precise roles of CB1 and CB2 and their cognate ligands in ES
cells are not known. We observed significant induction of CB1 and CB2 cannabinoid receptors during the hematopoietic
differentiation of murine ES (mES)-derived embryoid bodies. Furthermore, mES cells as well as ES-derived embryoid bodies at
days 7 and 14, expressed endocannabinoids, the ligands for both CB1 and CB2. The CB1 and CB2 antagonists (AM251 and
AM630, respectively) induced mES cell death, strongly suggesting that endocannabinoids are involved in the survival of mES
cells. Treatment of mES cells with the exogenous cannabinoid ligand D
9-THC resulted in the increased hematopoietic
differentiation of mES cells, while addition of AM251 or AM630 blocked embryoid body formation derived from the mES cells.
In addition, cannabinoid agonists induced the chemotaxis of ES-derived embryoid bodies, which was specifically inhibited by
the CB1 and CB2 antagonists. Conclusions. This work has not been addressed previously and yields new information on the
function of cannabinoid receptors, CB1 and CB2, as components of a novel pathway regulating murine ES cell differentiation.
This study provides insights into cannabinoid system involvement in ES cell survival and hematopoietic differentiation.
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INTRODUCTION
Murine embryonic stem (mES) cells, derived from the inner cell
mass of preimplanted embryos, are pluripotent and retain the
ability to differentiate into cells of all three germ layers of the
developing mouse embryo. Understanding the regulatory mech-
anisms responsible for the hematopoietic differentiation of mES
cells is crucial in defining the pathways and molecular events that
control germ layer determination and tissue formation.
ES cells also exhibit the capacity to contribute to a wide range of
well-defined cell types when using several in vitro models of
differentiation. In vitro differentiation assays using ES cultures
involve the removal of Leukemia inhibitory factor (LIF) and
separation of the cells from the feeder layer under conditions that
promote the formation of embryonic stem cell aggregates, termed
embryoid bodies (EBs). These EBs contain a number of different
cell types [1–2]. Molecular assays in combination with in vitro
differentiation assays of ES cells provide insights into the early
molecular events associated with lineage specification.
Although the in vitro hematopoietic differentiation of ES cells has
been characterized at both the cellular and molecular levels, the
pathways that regulate the hematopoietic differentiation of ES
cells are not well defined [3,4]. ES cells can be expanded ex vivo as
undifferentiated cells that retain a normal karyotype or, alterna-
tively, can be differentiated ex vivo into cell types of all three germ
layers [2]. LIF is required to maintain the undifferentiated state of
ES cells, whereas withdrawal of LIF initiates the formation of EBs
and cellular differentiation [3,4]. Even though EBs are far less
organized than the actual embryo, they can partially mimic the
spatial organization in the embryo. The developmental mechan-
isms of vascular and hematopoietic systems in EBs are similar to
those in the yolk sac [5–8].
G-coupled protein receptor (GPCR) members play a central
role in regulating the spatial distribution of immature and mature
hematopoietic cells, including their release into the circulation and
homing to hematopoietic tissue. GPCRs have been linked to many
functions, including cell proliferation, maturation, survival,
apoptosis, and migration [9–12]. The CB1 and CB2 cannabinoid
receptors are members of the GPCR family. The CB2 receptors
are primarily expressed in myeloid, macrophage, erythroid,
lymphoid and mast cells [13]. The brain cannabinoid receptor
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splenocytes and T cells, but mostly CB1 receptors are expressed at
high levels in the central nervous system (CNS) where they
regulate the attenuation of synaptic transmission and psychoactiv-
ity [14–20]. To date, several endogenous lipids that are derivatives
of long-chain fatty acids have been isolated and characterized as
natural ligands, and are termed endocannabinoids. Endocanna-
binoids are synthesized in vivo by various tissues on demand
through cleavage of membrane precursors, and are involved in
short range signaling processes [21]. Four types of endogenous
compounds have been discovered so far and been proposed to act
as endocannabinoids: 1) anandamide (AEA) (N-arachidonoyl-
ethanolamine) and some of its derivatives; 2) 2-arachidonoylgly-
cerol (2-AG) and noladin ether (2-arachidonoyl glycerol ether); 3)
virodhamine (o-arachidonoyl-ethanolamine); and 4) N-arachido-
noyl-dopamine (NADA). Since their discovery, endocannabinoids,
anandamide and 2-AG in particular, have been implicated in
physiological functions as well as in many pathological conditions.
Endocannabinoids have been isolated from the brain as well as
from the spleen and other peripheral tissues [21]. The presence of
endocannabinoids in hematopoietic and immune cells suggests
that CB2 and its endogenous ligands may play critical physiolog-
ical roles in the regulation of inflammatory reactions and immune
responses [22]. However, the expression, function and the precise
roles of CB1 and CB2, as well as their cognate ligands, in ES cells
are unknown.
Natural cannabinoids are the constituents of marijuana plants
[23]. D
9-tetrahydrocannabinol (=THC), a major psychoactive
constituent of marijuana, interacts with both the CB1 and CB2
receptors, thereby eliciting a variety of pharmacological responses
in vitro and in vivo [24]. Many agonists have been developed that
are selective for the CB1 (ACPA, ACEA) and CB2 (JWH-015,
JWH-133) receptors and have significantly higher affinities for one
receptor over the other [24–29]. Furthermore, various antagonists
that specifically inhibit the CB1 or CB2 receptors have also been
developed. Anandamide and 2-AG are endogenous ligands,
members of the eicosanoid class of cannabinoids, which are
arachidonic acid derivatives and are structurally different from
other cannabinoid classes.
We hypothesize that CB1 and CB2 play regulatory roles in the
hematopoietic differentiation of ES cells and that endocannabi-
noids are important for the survival of ES cells. Here, we
examined the expression and function of CB1 and CB2 in mES
cells and determined their role in mES cell hematopoietic
differentiation. We also analyzed the expression of endocannabi-
noids in mES cells and determined the effects of cannabinoid
antagonists on ES cell survival.
RESULTS
Expression of CB1 and CB2 in murine embryonic
stem cells and murine embryoid bodies
To examine the expression of CB1 and CB2 in mES cells, we
performed RT-PCR analysis on control undifferentiated ES cells
(Rosa26.6 and E14 ES cells) and on EBs derived from the
secondary hematopoietic differentiation of these two ES cell lines
at different time points as indicated. We found that CB1 and CB2
mRNAs and proteins were induced substantially in hematopoietic
differentiated EBs as compared to control ES cells. As shown in
Figure 1A and B, a significant induction of CB1 and CB2 gene
Figure 1. Expression of CB1 and CB2 in Rosa26.6 (Panel A) and E14 (Panel B) ES cells. Cells were washed with PBS, and then RNA was isolated and
analyzed by RT-PCR using specific primers for CB1, CB2, GAPDH and CXCR4. Panel C: RT-PCR analysis of the in vitro differentiation of Rosa26.6 ES cells,
using specific primers for GAPDH, Flk-1, PECAM-1 and Sca-1. EBs: Embryoid bodies. ES cells: undifferentiated control ES cells. The following primers
were used:
GAPDH: 292 bp
S5 9-CTCACTGGCATGGCCTTCCG-39
AS 59-ACCACCCTGTTGCTGTAGCC-39
CB1: 430 bp
S5 9-CGTGGGCAGCCTGTTCCTCA-39
AS 59-CATGCGGGCTTGGTCTGG-39
CB2: 479 bp
S5 9-CCGGAAAAGAGGATGGCAATGAAT-39
AS 59CTGCTGAGCGCCCTGGAGAAC-39
PECAM-1: 260 bp
S5 9-GTCATGGCCATGGTCGAGTA-39
AS 59-CTCCTCGGCATCTTGCTGAA-39
Flk-1: 239 bp
S5 9-CACCTGGCACTCTCCACCTTC-39
AS 59-GATTTCATCCCACTACCGAAAG-39
doi:10.1371/journal.pone.0000641.g001
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from both Rosa26.6 and E14 ES cells, while undifferentiated mES
cells had little expression of CB1 and CB2. Interestingly,
expression of CXCR4 (a member of the GPCR family) was
observed in undifferentiated ES cells and was not changed during
ES cell differentiation (Fig. 1A). We also analyzed several
hematopoietic markers in these hematopoietic EBs. We observed
induction of Sca-1 expression, as well as induction of PECAM-1
and Flk-1 expression during ES cell differentiation (Fig. 1C), which
is in agreement with other published reports [30].
Next, CB1 and CB2 protein expression was analyzed in
Rosa26.6 and E14 ES cells by Western blot analyses using two
different specific sets of CB1 and CB2 antibodies, commercially
available from Chemicon (set 1) (Fig. 2) and Sigma (set 2) (data not
shown). Both sets of specific CB1 and CB2 antibodies showed
induction of CB1 and CB2 protein expression during ES cell
differentiation in day 8 and 11 EBs derived from secondary
differentiation, as demonstrated by Western blot analysis (Fig. 2)
and immunohistochemistry (data not shown). These results showed
that CB1 and CB2 are both upregulated during the hematopoietic
differentiation of ES cells and imply that CB1 and CB2 may have
important regulatory roles in ES cell differentiation.
Expression of endocannabinoids in mES cells and
embryoid bodies derived from mES cells at days 7
and 14
To examine whether mES cells as well as EBs derived from mES
cells express endocannabinoids, mES cells were analyzed for the
expression of various fatty acids and their ethanolamide and
monoglyceride derivatives using LC-APCI-MS analysis [31]. As
shown in Figure 3, derivations of the endocannabinoids were
detected and quantitated in mES cells and EBs at days 7 and 14.
The level of anandamide (AEA) expression in the mES cells was
much lower as compared to that of 2-AG, and AEA was not
detected at all in EBs at days 7 and 14. The expression levels of: 2-
AG, docosahexaenoic acid (DHA), arachidonic acid (AA), 2-oleoyl
glycerol (2-OG), eicosapentaenoic acid (EPA), 2-docosahexaenoyl
glycerol (2-DHG) and 2-eicosapentaenoyl glycerol (2-EPG), were
abundant in mES cells, and EBs at days 7 and 14. Endocanna-
binoid levels in the embryonic stem cells were correlated to the
number of mES cells (data not shown). These analyses showed that
mES cells abundantly express endocannabinoids, specifically 2-AG
which might be important for their survival. Furthermore, since
both EBs at days 7 and 14 express endocannabinoids, this could
suggest that endocannabinoids may play a role in the hematopoi-
etic differentiation of mES cells.
Effects of exogenous and endogenous cannabinoid
ligands on the chemotaxis of mES cells
A major function of the 2-AG endocannabinoid is the stimulation
of migration in B lymphocytes [32]. Since CXCR4 and its cognate
ligand SDF-1a are involved in hematopoietic stem cell chemotaxis,
migration and homing [33–45], and since CXCR4, CB1 and CB2
are members of the GPCR family, we therefore studied whether
cannabinoid ligands act as chemotactic or chemokinetic agents for
ES cells. We analyzed the effects of the endogenous cannabinoid
ligand 2-AG, the exogenous ligand D
9-THC and the specific CB2
receptor agonist, JWH-015, on the chemotaxis of undifferentiated
ES cells as well as day 10 EBs derived from secondary hemato-
poietic differentiation.
The chemotaxis assays were performed using Costar Transwells
(Corning-Costar, Cambridge, MA). As shown in Figure 4,
chemotaxis was observed with differentiated EBs at day 10 in
the presence of the D
9-THC, 2-AG and JWH-015 cannabinoid
ligands, while the chemotaxis of undifferentiated ES cells was very
low. This chemotaxis was inhibited by the CB1 and CB2 specific
inhibitors, AM251 and AM630, respectively. Thus, cannabinoid
ligands, such as 2-AG, exogenous D
9-THC and JWH-015 induce
the chemotaxis of hematopoietic differentiated ES-derived EB
cells, mediated through both the CB1 and CB2 receptors.
Effects of cannabinoid inhibitors on the survival of
Rosa ES cells
To analyze the effects of D
9-THC on the survival of Rosa ES cells,
the Rosa ES cells were untreated or treated with D
9-THC (1 mM)
or with the specific inhibitors for CB1 (AM251) or CB2 (AM630)
(in the absence of D
9-THC) for 48 hours. In addition, Rosa ES
cells were treated with DMSO (0.01%) or with methanol (0.01%)
as vehicle controls. After 48 hours, cells were analyzed for
Figure 2. The expression of CB1 and CB2 receptors in Rosa26.6 and
E14 ES cells as analyzed by Western blot analysis. Cells were lysed in
RIPA buffer and 100 mg of total cell lysates were analyzed by SDS-
PAGE, followed by Western blotting with CB1 or CB2 specific antibodies
(at a dilution of 1:500). The cell lines 293T and SH-SY5Y were used as
negative and positive controls, respectively, for CB1 expression. Actin
was used as a control for loading. ES cells: undifferentiated ES cells; EBs:
Embryoid bodies at different time points as indicated.
doi:10.1371/journal.pone.0000641.g002
Figure 3. Comparison of endocannabinoid levels in mES cells and EBs
at days 7 and 14, when the number of cells in each group is
normalized to 10
7 (=1e
7). The groups depict the logarithms of each
value. AEA, DHEA and EEA endocannabinoid levels were detected but
were lower than the limit of quantitation (,0.05 ng/1e
7 cells) for the
number of cells analyzed.
doi:10.1371/journal.pone.0000641.g003
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were observed upon treatment with DMSO or methanol as
compared to the cannabinoid-treated ES cells. D
9-THC also had
no apoptotic effects on the Rosa ES cells. However, both inhibitors
(AM251 and AM630) induced significant cell death in the absence
of D
9-THC (Fig. 5). These results suggest that endocannabinoids,
either secreted by ES cells and/or by the Primary Embryonic
Fibroblast (PEF) feeder cells, are important for the survival of ES
cells and that specific inhibition of these endogenous ligands by
inhibitors for CB1 and CB2 results in cell apoptosis.
Effects of endocannabinoids and exogenous
cannabinoid ligands on the differentiation of mES
cells
To examine the effects of exogenous cannabinoid ligands on ES
cell differentiation, the ligand D
9-THC (1 mM) was added to Rosa
ES cells in DMEM medium. The CB1 specific inhibitor AM251
(1 mM) and the CB2 specific inhibitor AM630 (1 mM) were used
for blocking the effects of cannabinoid ligands on ES cell
differentiation, as indicated. The addition of AM251 or AM630
or addition of the control vehicle DMSO (0.01%) or methanol
(0.01%) was performed during the primary differentiation stage
and secondary hematopoietic differentiation of Rosa ES cells into
EBs. ES cells were preincubated with AM251 or AM630 or with
control vehicle DMSO or methanol for 30 min. The cells were then
washed and further cultured for the in vitro hematopoietic different-
iation over 14 days in the presence or absence of D
9-THC, as
described above. The number of EBs was counted after 14 days. As
shown in Figure 6, D
9-THC induced an increase in the number of
EBs as compared to the control ES cells. However, when D
9-THC
was administered in the presence of AM251 or AM630, there was
a decrease in the number of EBs (up to 70–75% inhibition).
Interestingly, AM251 or AM630 alone also inhibited the number of
EBs derived from ES cells (Fig. 6). This result suggests that these
inhibitors block the effects on ES cell-derived EBs that are mediated
by the endogenous endocannabinoid ligands, secreted by either the
ES cells or PEF feeder cells, and that inhibition of CB1 and/or CB2
receptor-mediated effects, by specific CB1 and CB2 inhibitors,
significantly blocks EB formation.
Figure 4. Effects of cannabinoid ligands on the chemotaxis of ES cells and hematopoietic differentiated ES-derived EB cells (EBs-day 10). Cells
were placed in the upper well of the transwell in the presence or absence of specific inhibitors, as indicated. The ligands: 2-AG, D
9-THC, JWH-015 and
SDF-1a were placed in the lower chambers. Data show the mean value of 3 independent experiments (mean6SD). Error bars indicate SD. * P values
with asterisk (*, P,0.05) show significant differences from control with media alone.
doi:10.1371/journal.pone.0000641.g004
Cannabinoid System in mES Cell
PLoS ONE | www.plosone.org 4 July 2007 | Issue 7 | e641DISCUSSION
Recent work has linked changes in immune function to biologic
and therapeutic targeting of cannabinoid receptors [13]. Canna-
binoid receptor expression offers a new principle for regional
immune homeostasis and disease susceptibility, and extends and
refines the rationale for CB2-targeted immunotherapy in immune
and inflammatory diseases. Therefore, elucidation of the effects of
the cannabinoid system (especially CB2-transduced signaling) on
stem cell self-renewal, proliferation, and differentiation should lead
to the creation of new therapeutic approaches for hematological
disorders as well as novel strategies involving pharmacological
support for hematopoietic stem cell (HSC)-based therapies.
Here, we have characterized the expression and function of
CB1 and CB2 cannabinoid receptors in murine ES cells and in
ES-derived EBs, and examined the role of endocannabinoids and
their cognate receptors, CB1 and CB2, as novel components of
a new pathway important in murine ES cell differentiation. To test
the hypothesis that the CB1 and CB2 receptors may have
complementary roles in the hematopoietic differentiation of ES
cells, we employed ES-derived differentiation methods using the
Embryoid Body assay, which is well-controlled, easily manipulated
and physiologically representative of the in vivo system. We
demonstrated significant upregulation of CB1 and CB2 mRNA
and protein in hematopoietic EBs at days 8 and 11 in both
Rosa26.6 ES cells and E14 cells. The cannabinoid agonist
D
9-THC and the endocannabinoids induced the chemotaxis of
EBs derived from either Rosa26.6 or E14 cells at day 10.
Treatment of mES cells with the CB1 cannabinoid antagonist
AM251 or with CB2 cannabinoid antagonist AM630 resulted in
the death of these cells, indicating the involvement of endocanna-
binoids in mES cell survival. Murine ES cells were found to
abundantly express endocannabinoids including the endocanna-
binoid 2-AG, which may play a role in mES cell survival.
Furthermore, EBs at days 7 and 14 also express endocannabi-
noids, suggesting that endocannabinoids mediate the hematopoi-
etic differentiation of mES cells, since the numbers of EBs derived
from the mES cells was inhibited in the presence of AM251 and
AM630. These results show that both CB1 and CB2 receptors, as
well as their cognate agonists, are important regulators of mES cell
survival and differentiation.
The availability of stem cells provides new approaches for the
treatment of human diseases. Elucidation of the regulatory
mechanisms responsible for stem cell differentiation is crucial for
the application of ES cells to human diseases [46]. Mouse ES cells
undergo unlimited self-renewal in the presence of the cytokine
LIF, while retaining their multi-lineage differentiation capacity.
Withdrawal of LIF and aggregation of cells lead to the
differentiation of structures known as embryoid bodies (EBs).
During differentiation, certain genes are upregulated and several
others are downregulated in an intricately controlled fashion.
Figure 5. Effects of D
9-THC and cannabinoid inhibitors (AM251 and AM630) on Rosa ES cell survival. Rosa ES cells were either untreated (as
control) or treated with D
9-THC, control DMSO (0.01%), control methanol (0.01%), or with the inhibitors AM251 (for the CB1 receptor) or AM630 (for
the CB2 receptor), as indicated. After 48 hours, the cells were analyzed for their viability by light microscopy. This is a representative experiment out
of three experiments.
doi:10.1371/journal.pone.0000641.g005
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self-renewal or differentiation is decided by the interplay between
intrinsic factors and extrinsic or selective signals. However, to date
the intrinsic biology of these ES cells remains poorly defined. The
stimulation of ES cell self-renewal was found to be restricted to LIF
and related cytokines of the IL-6 family, which signal through the
gp130 receptor via JAK kinase-mediated STAT3 activation [46–
48]. PI3-kinase signaling was also observed to play an important
role in mES cell survival and cell cycle progression [49]. Recently,
STAT3 was reported to be the key downstream transcription
factor of the LIF/gp130 signaling pathway in mES cells.
Moreover, the Ca
2+ signaling pathway in mES cells was also
shown to mediate mES cell function [50]. Based on our results, we
suggest that the cannabinoid system is an additional pathway
involved in mES cell survival and differentiation.
The majority of directed differentiation protocols utilize an initial
EB aggregation step. Therefore, the early-acting differentiation-
promoting activities occurring inside the EBs are largely unknown.
Based on our results, we suggest that exogenous cannabinoids can
induce or promote hematopoietic differentiation. mES cells express
both CB1 and CB2 receptors and both receptors are functional.
Addition of exogenous selective cannabinoidagonistsaugmented the
embryoid body formation derived from mES cells, indicating that
cannabinoid ligands induced the hematopoietic differentiation of
mES cells through CB1 and CB2 in both mES cells and EB-derived
mES cells. Interestingly, CB2 receptors were recently found to
promote mouse neural stem cell proliferation (NSCP) [47].
Cannabinoid agonists also increased in vitro NSCP proliferation
and neurosphere generation [47]. The contribution of endocanna-
binoids to neurogenesis within the subventricular zone was
recognized due to the reduced proliferation of neural precursors in
CB1 receptor knockout mice [47]. Thus, these observations together
with our results strongly suggest that both CB1 and CB2 activation
are involved in the maintenance of mES cells and that the
endocannabinoid system is essential in stem cell survival and stem
cell hematopoietic differentiation.
MATERIALS AND METHODS
Antibodies, and chemical and biological compounds
Anti-CB1 and anti-CB2 antibodies (ABR-Affinity
BioReagents, Golden, CO) were used for immunostaining. The
immunophenotyping of CB2 was confirmed with the use of
another anti-CB2 antibody obtained from Sigma (St. Louis, MO).
The cannabinoid ligands D
9-THC (THC), JWH133, methanan-
damide, and CP55940 were also obtained from Sigma. ACEA and
the cannabinoid receptor antagonists AM251 and AM630 were
purchased from Tocris (Ellisville, MO). G-CSF (Neupogen) was
obtained from Amgen Inc. (Thousand Oaks, CA). MethoCult
03434 (for mouse cells) was obtained from StemCell Technologies
(Vancouver, BC, Canada). The deuterated endocannabinoids used
as internal standards in the LC-APCI-MS analysis were
synthesized in-house at the Center for Drug Discovery, North-
eastern University (Boston, MA) following reported methods [31].
RT-PCR analysis of CB1 and CB2 expression
RNA from total mES cells was extracted using the RNeasy Mini
Kit (Qiagen, Valencia, CA) following the manufacturer’s protocol.
A QIAshredder spin column and DNase digestion were included
in the isolation procedure to limit the possibility of PCR
amplification of CB1 and CB2 from genomic DNA. cDNA and
PCR amplification were performed with the BD Biosciences
TITANIUM One-Step RT-PCR Kit using 200 ng of RNA as
a template for first-strand synthesis. CB1 was amplified using
primers: 59-CGT GGG CAG CCT GTT CCT CA-39 and 59-
CAT GCG GGC TTG GTC TGG-39, which yield a product of
403 bp. CB2 was amplified using: 59-CCG GAA AAG AGG ATG
GCA ATG AAT-39 and 5-CTG CTG AGC GCC CTG GAG
AAC-39, which yield a product of 479 bp. GAPDH was used as
a positive control with primers: 59-CTC ACT GGC ATG GCC
TTC CG-39 and 59-ACC ACC CTG TTG CTG TAG CC-39,
which yield a product of 292 bp. The template was first denatured
at 94uC for 2 min followed by 35 cycles (94uC for 30 sec, 58uC for
30 sec and 68uC for 1 min), followed by 68uC for 2 min in
a myCycler Personal Thermal Cycler (Bio-Rad Laboratories, Inc).
Aliquots (20 ml) of the PCR products were run on a 1.2% agarose
gel containing 0.5 mg/ml ethidium bromide.
Origination of embryoid bodies from ES cells
The Rosa26.6 ES cell line was obtained from Dr. Stuart Orkin
(Children’s Hospital, Harvard Medical School); The E14 and
GFP-E14 cell lines were obtained from Dr. Bing Lim (Beth Israel
Deaconess Medical Center, Boston). Culture and maintenance of
ES cells in an undifferentiated state were performed as described
previously [1]. Briefly, ES cells were maintained on a mouse PEF
feeder cell line in ES medium containing Dulbecco’s modified
Eagle’s medium (DMEM) with high glucose, 10 ng/ml murine
leukemia inhibitory factor (mLIF; Chemicon International,
Temecula, CA), 15% fetal calf serum (FCS; Hyclone, Logan,
UT), 1 mM sodium pyruvate, 2 mM glutamine, 0.1 mM non-
essential amino acid, 100 mM monothioglycerol (MTG; Sigma),
50 U/ml penicillin, and 10 mg/ml streptomycin. The ES cell lines
were regularly analyzed, by using an ES cell characterization kit
(Chemicon), for determination of alkaline phosphatase activity and
detection of surface markers and transcription factors that are
expressed by undifferentiated ES cells, such as Oct-4, Rex-1,
SSEA-1 and Genesis (Fox D-3).
In vitro hematopoietic differentiation of ES cells was performed
as described, essentially according to the protocol of StemCell
Technologies. The embryoid body (EB) method involves two steps:
first, spherical cell aggregates (termed embryoid bodies=EBs) are
Figure 6. Effects of D
9-THC on the differentiation of ES cells. Rosa ES
cells were either untreated or treated with D
9-THC in the presence or
absence of cannabinoid inhibitors (AM630 and AM251), as indicated.
After 14 days, the number of EBs was counted. Data represent the
mean value of 3 independent experiments (mean6SD). * P values with
asterisk (*, P,0.05) show significant differences from ES cells.
doi:10.1371/journal.pone.0000641.g006
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derivatives (=Primary Differentiation); second, these aggregates
are selected for hematopoietic precursors and expanded with
growth factors such as IL-3 and IL-6 (=Secondary Hematopoietic
Differentiation). Briefly, EBs were generated in 1% methylcellulose
cultures (1610
4 ES cells per 35-mm Petri dish). To promote primary
differentiation into EBs, ES cells were cultured in ES differentiation
medium containing Iscove’s modified Dulbecco’s medium (IMDM),
15% FCS (StemCell Technologies), 2 mM glutamine, 150 mM
MTG, and 40 ng/ml murine stem cell factor (mSCF). After 8 days
of differentiation, the EBs were collected and washed. 1610
4 of
single cells were seeded on 1% methylcellulose from the secondary
hematopoietic differentiation medium. 15% FBS, 2 mM L-gluta-
mate, 150 mM MTG, 20% BIT (10% BSA, 10 mg/ml insulin,
200 mg/ml transferrin), 150 ng/ml mSCF, 30 mg/ml IL-3, 30 mg/
ml IL-6 and 3 U/ml Epo were added to the culture to promote
hematopoietic differentiation. Cells were processed for Wright-
Giemsa staining, RT-PCR and Western blot analyses at different
times of EB culture differentiation, as indicated.
To determine the characteristics of various types of hemato-
poietic progenitors present during ES cell differentiation, EBs from
ES cell lines were collected from the cultures at days 8 and 11
(from the day of replating) to obtain the hematopoietic
progenitors. Cytospin preparation of these cells was stained with
Wright-Giemsa and examined under a light microscope. Un-
differentiated ES cells have a large nucleus, minimal cytoplasm,
and one or more prominent dark nucleoli. Hematopoietic
progenitors found in EB-day 14 cultures were identified by the
morphology of erythroids, megakaryocytes, monocytes/macro-
phages, granulocytes and mast cells, as analyzed by field
microscopy.
Chemotaxis assays
The chemotaxis assays were performed using 5 mm-pore size and
6.5 mm-diameter Costar Transwells (Corning-Costar, Cambridge,
MA), as previously described [30]. Cells were washed twice with
Hank’s balanced salt solution (HBSS) medium, resuspended in
100 ml medium [Iscove’s Modified Dulbecco’s Medium (IMDM)
plus 0.5% BSA] and placed in the upper chamber of the
Transwells. In the lower chamber, 600 ml of medium with or
without ligand was placed, as indicated. After 4 hours of
incubation at 37uC and 5% CO2, the upper chamber was
removed and the number of migrated cells was determined using
a CASY/TTC cell counter. The ligand D
9-THC (D
9-Tetrahy-
drocannabinol) and the endogenous ligand 2-AG (Cayman
Chemical, Ann Arbor, MI, Catalog #62165) were added at
1 mM concentrations in IMDM media. The specific CB2 receptor
agonist JWH-015 (Tocris Catalog number #1341) was also tested
at a 1 mM concentration. The CB1 specific inhibitor AM251
(1 mM) (Tocris Catalog number #1117) and the CB2 specific
inhibitor AM630 (1 mM) (Tocris Catalog number #1120) were
used to block the effects of cannabinoid ligands on ES cell
chemotaxis. For the inhibition studies, cells were preincubated
with the inhibitor agonists for 30 min as indicated. SDF-1 alpha
(25 ng/ml) was used as a positive control (PeproTech Inc., Catalog
number #250-20A).
Survival assays
2610
4 Rosa ES cells (per well of 96 wells), CB1 and CB2 specific
ligands as well as inhibitors were added to the cell culture as
indicated. A 1 mM final concentration was used for CP55940 (CB1
and CB2 agonists), ACEA (CB1 ligand) and JWH133 (CB2
ligand). A 1 mM final concentration of both AM251 (CB1
inhibitor) and AM630 (CB2 inhibitor) was used, as indicated.
Cells were incubated for two days in a humidified CO2
atmosphere. The MTT assay was performed according to the
Promega manual (Promega Cat# G5421), and the absorbance at
490 nm was then recorded.
Endocannabinoid levels in embryonic stem cells
The extraction procedure for the calibration standards was
performed as described [31]. Cells (mES cells, EBs at day 7 and
EBs at day 14), at various concentrations as indicated, were
homogenized in cold acetone:PBS, pH 7.4 (3:1). The homoge-
nates were sonicated for 30 seconds prior to centrifugation at
20,800 g for 5 minutes. The acetone from the resulting super-
natants was removed under nitrogen. To the remaining superna-
tant, 50 ml PBS, one volume of methanol and two volumes of
chloroform were added for liquid-liquid phase extraction of the
lipids. The two phases were separated by centrifugation and the
bottom organic layer was evaporated under nitrogen. The cell
samples were reconstituted in 50 ml ethanol.
The system used for analysis was a TSQ Quantum Ultra triple
quadrupole mass spectrometer (Thermo Electron, San Jose, CA)
with an Agilent 1100 HPLC on the front end (Agilent
Technologies, Wilmington, DE). The mobile phase consisted of
10 mM ammonium acetate (pH 7.3 using ammonium hydroxide;
A) and 100% methanol (B). Separation of each analyte was
achieved using a Zorbax SB-CN 2.1650mm, 5 mm, 80A ˚, column
(Agilent Technologies) and gradient elution; the autosampler was
kept at 4uC to prevent analyte degradation [31]. Eluted peaks were
ionized via atmospheric pressure chemical ionization (APCI) and
detected by each analyte’s SRM transition [31].
Statistical analysis
The results are represented as the mean 6 S.D. The significance
of the data was determined by a two-tailed t test. P,0.05 was
considered statistically significant.
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